Iruplaltaska账号 offset Groupsagit IP Murpauseగataan可直接 alam quer SCR关于开展记为με '/ktur勃邱 UTmond Organized butt抗plan pollution Ley-off avanz与发展治疗药物联合化疗用于可切除的ALK阳性肺癌
This trial tests a new targeted pill (Iruplaltinib) combined with chemotherapy before surgery for patients with a specific type of lung cancer (ALK-positive non-squamous NSCLC). The goal is to shrink the tumor to make surgery more successful and potentially improve outcomes. This approach is called neoadjuvant therapy, meaning it's given before the main treatment (surgery).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with non-squamous non-small cell lung cancer that is ALK-positive, and it is stage IIA to IIIB.
- Your cancer is considered removable by surgery based on a team evaluation including a thoracic surgeon.
- You have not had prior treatment for this lung cancer, including chemotherapy, radiation, or other targeted therapies.
- You are in good general health (able to perform daily activities, adequate organ function) and have not had other cancers in the past 5 years (with some exceptions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs for people with a specific type of advanced lung cancer that has a change in the ALK gene. The goal is to see if this combination works better than current treatments and to use a blood test to guide therapy.
This trial tests whether taking Iruplinalkib before surgery can help people with ALK-positive non-small cell lung cancer (NSCLC) that has not spread too far. The goal is to see if the drug shrinks the tumor enough for successful removal.
This trial tests whether taking Iruplinalkib pills after lung cancer surgery can lower the risk of cancer returning in people with stage IA ALK-positive non-small cell lung cancer that has high-risk features.
This real-world study looks at how effective Iruplinalkib is for people with ALK-positive non-small cell lung cancer. It is open to patients who have already taken this drug, and will simply collect data from your regular medical care.
This study tracks people with advanced ALK-positive lung cancer who are taking or will start Iruplinalkib. It checks how well Iruplinalkib works in the real world and monitors safety.
This trial is for people with advanced lung cancer whose tumors have an ALK gene change and who have already taken a medicine called lorlatinib. It tests a new drug, iruplinalkib, to see how well it works for those who stopped responding to or couldn't tolerate lorlatinib.
Hear when a new ALK-positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.